Live Breaking News & Updates on Penx Acip

Stay updated with breaking news from Penx acip. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Quest adds pTau217 to Alzheimer's test portfolio

Quest Diagnostics Inc. expanded its Alzheimer’s disease (AD) portfolio with a blood-based biomarker test for phosphorylated tau 217 (pTau217). The test joins the company’s plasma tests for p-tau181, beta-amyloid 42/40 ratio and ApoE genetic risk as well as several cerebrospinal fluid tests for Alzheimer’s. ....

Quest Diagnostics Inc , Quest Diagnostics , Helmholtz Diabetes Center , Cancer Induced Cachexia , Penx Acip , Bioworld Medtech , Quest Diagnostics Inc , Alzheimers Disease , Ptau 217 , P Tau217 , Laboratory Corporation Of America Holdings Inc , Quanterix Corp , Meso Scale Diagnostics Llc , Neurocode Usa Inc , Neurology Psychiatric ,

Lumicell shines a light on residual breast cancer with FDA approvals

Lumicell Inc. sees a brighter future now that it has secured U.S. FDA approval for both its new drug application for Lumisight (pegulicianine) optical imaging agent and premarket approval for the Lumicell direct visualization system . The company markets the two together as the Lumisystem to detect and resect residual breast cancer. Newton, Mass.-based Lumicell expects the Lumisystem will be available in the fourth quarter of 2024, Lumicell President and Chief Operating Officer Howard Hechler told BioWorld. ....

Howard Hechler , Lumicell Inc , Lumicell President , Chief Operating Officer Howard Hechler , Helmholtz Diabetes Center , Cancer Induced Cachexia , Penx Acip , Bioworld Medtech , Lumicell Inc , Breast Cancer ,

Earlybird looks to catch innovative tech with new €173M fund

The €173 million (US$187 million) in capital that Earlybird Health recently raked in from investors will go towards bolstering investment in European health care startups, many of which are still recovering from the impact of COVID-19, Thom Rasche, a partner at Earlybird Health, told BioWorld. The fund is looking to invest in the technologies that can improve patient care. ....

Thom Rasche , Earlybird Health , Helmholtz Diabetes Center , Cancer Induced Cachexia , Penx Acip , Bioworld Medtech , Earlybird Ventures ,

Theryq, Gustave Roussy given €38M for cancer radiotherapy

Theryq SAS and Gustave Roussy, a European center for cancer research, were given €38 million (US$40.1 million) in funding by Bpifrance, the French public sector investment bank, to further develop Flashdeep, a flash radiotherapy device that uses extremely high energy electron (VHEE) radiation to treat cancers that are resistant to traditional treatments. ....

Gustave Roussy , Helmholtz Diabetes Center , Cancer Induced Cachexia , Penx Acip , Bioworld Medtech , Gustave Roussy Cancer Center , Gustave Roussy Institute , Theryq Sas , Bpifrance Sa ,

Clarius receives CE mark for latest wireless ultrasound scanner

Clarius Mobile Health Inc. received CE mark for its latest wireless hand-held whole-body ultrasound scanner, the Clarius PAL HD3. The scanner combines both phased and linear arrays on a single head which provides high image quality of superficial and deep anatomy allowing for better diagnostic capabilities and patient care. ....

Clarius Mobile Health Inc , Clarius Mobile Health , Helmholtz Diabetes Center , Cancer Induced Cachexia , Penx Acip , Bioworld Medtech , Face Mark , Clarius Mobile Health Inc , Clarius Pal Hd3 , Point Of Care Diagnostics ,